Source: FierceBiotech AbbVie has posted positive phase 3 psoriasis data on potential blockbuster risankizumab. The IL-23 antibody easily outperformed Johnson & Johnson’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year. Risankizumab aced all the primary and ranked secondary endpoints across three clinical trials, two…...
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
Source: PR Newswire Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced the appointment of Vince Ippolito as President and Chief Operating Officer. "I am extremely pleased to welcome Vince Ippolito to the Dermavant team," said Dr. Jacqualyn A. Fouse, Executive Chair of Dermavant.…...
Encore makes pipeline play, licensing psoriasis drug from Dr. Reddy’s
Source: FierceBiotech Encore Dermatology, formed two years ago as a vehicle for three ex-Valeant products, has picked up a late-stage pipeline drug via a deal with India's Dr. Reddy's Laboratories. The Malvern, Pennsylvania, company says it has licensed a steroid candidate developed by Dr. Reddy's Promius Pharma subsidiary that has…...
Prollenium Medical Technologies Inc. announces U.S. FDA approval for its cross-linked hyaluronic acid dermal filler
Source: PR Newswire Prollenium Medical Technologies Inc., a leading medical device manufacturer, announced today its United States (U.S.) Food and Drug Administration (FDA) approval for its cross-linked hyaluronic acid dermal filler. Ario Khoshbin, Founder and CEO, stated "This is definitely one of our proudest moments as an organization. FDA approval…...
Has the Brent Saunders price-hike limit become a de facto pharma rule?
Source: Nearly one year ago, as the pharma industry was beset by pricing scrutiny, Allergan CEO Brent Saunders pledged to keep his company’s hikes under 10%. Since then, that pricing rule has spread—even among companies that haven't publicly promised to do the same. Bernstein analyst Ronny Gal reports that for…...
Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101
Source: Globe Newswire Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Columbia University (“Columbia”) has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) pertaining to CAEL-101, which was licensed from Columbia…...
Allergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company’s Leading Plastic Surgery Portfolio
Source: PR Newswire Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan's wholly-owned subsidiary, Allergan Sales LLC agreed to acquire Keller Medical, Inc., a privately held medical device company and developer of the Keller Funnel®. The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces…...
Stuart Raetzman Appointed CEO of Nestlé Skin Health
Source: Business Wire Nestlé has appointed Stuart Raetzman as CEO of Nestlé Skin Health, effective immediately. “I am very pleased that Stuart will be leading Nestlé Skin Health as CEO. Nestlé’s purpose is to enhance quality of life and contribute to a healthier future. Under Stuart’s leadership, Nestle Skin Health…...
ALPHAEON Submits Biologics License Application for DWP-450 Neuromodulator
Source: PR Newswire ALPHAEON Corporation (www.alphaeon.com) today announced that its wholly-owned subsidiary, Evolus Inc., submitted a Biologics License Application (BLA) for DWP-450, a Botulinum toxin Type A, to the U.S. Food and Drug Administration (FDA) seeking approval for the treatment of adult patients with glabellar lines, also known as "frown…...
Ex-Kythera team raises $40M for dermatology clinical trials
Source: FierceBiotech Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets. The Series B round continues the rapid rise of Sienna, which has raised $86 million and bought Creabilis since it emerged helmed by the ex-Kythera Biopharmaceuticals team last year. Westlake Village, California-based Sienna…...